Published in J Antimicrob Chemother on February 08, 2007
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis (2008) 0.97
In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method. Antimicrob Agents Chemother (2013) 0.84
Uropathogen distribution and antimicrobial susceptibility in uncomplicated cystitis in Belgium, a high antibiotics prescribing country: 20-year surveillance. Eur J Clin Microbiol Infect Dis (2016) 0.76
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis (2006) 3.79
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med (2008) 3.23
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol (2004) 3.20
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother (2003) 3.13
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 3.06
qnr Gene nomenclature. Antimicrob Agents Chemother (2008) 2.81
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis (2010) 2.76
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother (2003) 2.19
[Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia]. Enferm Infecc Microbiol Clin (2006) 2.09
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
[Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin (2003) 1.61
Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther (2008) 1.60
Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother (2003) 1.54
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)]. Enferm Infecc Microbiol Clin (2003) 1.53
Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother (2008) 1.51
Plasmid-mediated quinolone resistance: an update. J Infect Chemother (2010) 1.48
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol (2004) 1.46
[Activity and penetration of linezolid and vancomycin against Staphylococcus epidermidis biofilms]. Enferm Infecc Microbiol Clin (2007) 1.43
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother (2011) 1.41
Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2003) 1.40
[Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant phenotype]. Enferm Infecc Microbiol Clin (2008) 1.39
National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother (2011) 1.38
Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother (2002) 1.37
Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control (2009) 1.27
Use of positive blood cultures for direct identification and susceptibility testing with the vitek 2 system. J Clin Microbiol (2004) 1.25
Plasmid-mediated quinolone resistance. Expert Rev Anti Infect Ther (2008) 1.25
Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis (2005) 1.22
Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. J Clin Microbiol (2013) 1.17
Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis (2009) 1.16
Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: a multicenter study. Intensive Care Med (2008) 1.14
Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase. Antimicrob Agents Chemother (2005) 1.13
Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol (2010) 1.12
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob Agents Chemother (2008) 1.10
Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol (2010) 1.09
Acquisition and cross-transmission of Staphylococcus aureus in European intensive care units. Infect Control Hosp Epidemiol (2009) 1.07
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin (2009) 1.07
Plasmid-mediated quinolone resistance in Australia. Microb Drug Resist (2006) 1.07
Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother (2006) 1.03
Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother (2013) 1.01
Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother (2009) 0.99
Effect of siliconized latex urinary catheters on the activity of carbapenems against Pseudomonas aeruginosa strains with defined mutations in ampC, oprD, and genes coding for efflux systems. Int J Antimicrob Agents (2003) 0.99
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother (2013) 0.97
Virulence profiles of bacteremic extended-spectrum β-lactamase-producing Escherichia coli: association with epidemiological and clinical features. PLoS One (2012) 0.97
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int J Antimicrob Agents (2011) 0.95
Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect (2011) 0.95
Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 0.94
Increased raw poultry meat colonization by extended spectrum beta-lactamase-producing Escherichia coli in the south of Spain. Int J Food Microbiol (2012) 0.94
Prevalence of IS(Aba1) in epidemiologically unrelated Acinetobacter baumannii clinical isolates. FEMS Microbiol Lett (2007) 0.93
Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A. Int J Antimicrob Agents (2011) 0.92
[Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates]. Enferm Infecc Microbiol Clin (2006) 0.92
Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother (2005) 0.91
[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin (2009) 0.91
[In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010]. Enferm Infecc Microbiol Clin (2012) 0.90
Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) (2014) 0.88
Analysis of plasmids encoding extended-spectrum beta-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville. Int J Antimicrob Agents (2007) 0.88
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost. Antimicrob Agents Chemother (2012) 0.88
Production of a plasmid-encoded OXA-72 β-lactamase associated with resistance to carbapenems in a clinical isolate Acinetobacter junii. Int J Antimicrob Agents (2011) 0.87
Evaluation of SDS-polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of Acinetobacter baumannii. J Basic Microbiol (2003) 0.87
Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin (2012) 0.86
[Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)]. Enferm Infecc Microbiol Clin (2008) 0.85
Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. J Antimicrob Chemother (2011) 0.85
Long-term control of endemic hospital-wide methicillin-resistant Staphylococcus aureus (MRSA): the impact of targeted active surveillance for MRSA in patients and healthcare workers. Infect Control Hosp Epidemiol (2010) 0.84
Outcome of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli: impact of microbiological determinants. J Infect (2013) 0.84
[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae]. Enferm Infecc Microbiol Clin (2006) 0.84
In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase. Int J Antimicrob Agents (2006) 0.83
Current management of bloodstream infections. Expert Rev Anti Infect Ther (2010) 0.83
Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents (2007) 0.83
Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii. Int J Antimicrob Agents (2012) 0.82
Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2011) 0.81
Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect (2007) 0.81
Neonatal sepsis caused by a CTX-M-32-producing Escherichia coli isolate. J Med Microbiol (2008) 0.81
In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii. Chemotherapy (2003) 0.79
Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Diagn Microbiol Infect Dis (2008) 0.79
In vitro adherence of Enterococcus faecalis and Enterococcus faecium to plastic biomaterials. Clin Microbiol Infect (1999) 0.79
Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol (2013) 0.79
Epidemiological and clinical features associated with colonisation/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems. Int J Antimicrob Agents (2012) 0.79
A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. J Microbiol Methods (2010) 0.78
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis (2013) 0.78
Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. J Antimicrob Chemother (2010) 0.78
Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest. Antimicrob Agents Chemother (2003) 0.78
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents (2006) 0.78